Back to results
US 2020/0392160 A1Published application
Macrocyclic compounds for treating disease
AssigneeTurning Point Therapeutics, Inc.
InventorsEvan W. Rogers, Jingrong J. Cui, Dayong Zhai, Han Zhang, Jane Ung, Wei Deng, Jeffrey Whitten
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to certain macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat disease, such as cancer.
Claims5
A compound of the formula I
- wherein
- each L is independently —C(R1)(R2)— or X;
- with the proviso that, when t is 1, then L is —C(R1)(R2)—;
- X is O, S, S(O) or S(O)2;
- each IV and R2 is independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl, —ORa, —OC(O)Ra, —OC(O)Ra, —OC(O)NRaRb, —OS(O)Ra, —OS(O)2Ra, —SRa, —S(O)Ra, —S(O)2Ra, —S(O)NRaRb, —S(O)2NRaRb, —OS(O)NRaRb, —OS(O)2NRaRb, —NRaRb, —NRaC(O)Rb, —NRaC(O)ORb, —NRaC(O)NRaRb, —NRaS(O)Rb, —NRaS(O)2Rb, —NRaS(O)NRaRb, —NRaS(O)2NRaRb, —C(O)Ra, —C(O)ORa, —C(O)NRaRb, —PRaRb, —P(O)RaRb, —P(O)2RaRb, —P(O)NRaRb, —P(O)2NRaRb, —P(O)ORa, —P(O)2ORa, —CN, or —NO2, or R1 and R2 taken together with the carbon or carbons to which they are attached form a C3-C6 cycloalkyl or a 4- to 6-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, mono- or bicyclic heteroaryl, 4- to 6-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, —ORe, —OC(O)Re, —OC(O)NReRf, —OC(═N)NReRf, —OS(O)Re, —OS(O)2Re, —OS(O)NReRf, —OS(O)2NReRf, —SRc, —S(O)Re, —S(O)2Re, —S(O)NReRf, —S(O)2NReRf, —NReRf, —NReC(O)Rf, —NReC(O)ORf, —NReC(O)NReRf, —NReS(O)Rf, —NReS(O)2Rf, —NReS(O)NReRf, —NReS(O)2NReRf, —C(O)Re, —C(O)ORe, —C(O)NReRf, —PReRf, —P(O)ReRf, —P(O)2ReRf, —P(O)NReRf, —P(O)2NReRf, —P(O)ORe, —P(O)2ORe, —CN, or —NO2;
- M is CR3 or N;
- M1 is CR4;
- each R3, R4, and R5 is independently hydrogen, deuterium, halogen, —ORc, —OC(O)Rc, —OC(O)NRcRd, —OC(═N)NRcRd, —OS(O)Rc, —OS(O)2Rc, —OS(O)NRcRd, —OS(O)2NRcRd, —SRc, —S(O)Rc, —S(O)2Rc, —S(O)NRcRd, —S(O)2NRcRd, —NRcRd, —NRcC(O)Rd, —NRc′C(O)ORd, —NRcC(O)NRcRd, —NRcC(═N)NRcRd, —NRcS(O)Rd, —NRcS(O)2Rd, —NRcS(O)NRcRd, —NRcS(O)2NRcRd, —C(O)Rc, —C(O)ORc, —C(O)NRcRd, —C(═N)NRcRd, —PRcRd, —P(O)RcRd, —P(O)2RcRd, —P(O)NRcRd, —P(O)2NRcRd, —P(O)ORc, —P(O)2ORc, —CN, —NO2, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl, or R4 and R5 taken together with the ring to which they are attached form a C5-C8 cycloalkyl, or a 5- to 8-membered heterocycloalkyl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, mono- or bicyclic heteroaryl, C5-C8 cycloalkyl, or 5- to 8-membered heterocycloalkyl is independently optionally substituted by deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, —ORe, —OC(O)Re, —OC(O)NReRf, —OC(═N)NReRf, —OS(O)Re, —OS(O)2Re, —OS(O)NReRf, —OS(O)2NReRf, —SRe, —S(O)Re, —S(O)2Re, —S(O)NReRf, —S(O)2NReRf, —NReRf, —NReC(O)Rf, —NReC(O)ORf, —NReC(O)NReRf, —NReS(O)Rf, —NReS(O)2Rf, —NReS(O)NReRf, —NReS(O)2NReRf, —C(O)Re, —C(O)ORe, —C(O)NReRf, —PReRf, —P(O)ReRf, —P(O)2ReRf, —P(O)NReRf, —P(O)2NReRf, —P(O)ORe, —P(O)2ORe, —CN, or —NO2;
- R6 is H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl is independently optionally substituted by deuterium, halogen, C3-C6 cycloalkyl, or 5- to 7-membered heterocycloalkyl, —ORe, —OC(O)Re, —OC(O)NReRf, —OC(═N)NReRf, —OS(O)Re, —OS(O)2Re, —OS(O)NReRf, —OS(O)2NReRf, —SRe, —S(O)Re, —S(O)2Re, —S(O)NReRf, —S(O)2NReRf, —NReRf, —NReC(O)Rf, —NReC(O)ORf, —NReC(O)NReRf, —NReS(O)Rf, —NReS(O)2Rf, —NReS(O)NReRf, —NReS(O)2NReRf, —C(O)Re, —C(O)ORe, —C(O)NReRf, —PReRf, —P(O)ReRf, —P(O)2ReRf, —P(O)NReRf, —P(O)2NReRf, —P(O)ORe, —P(O)2ORe, —CN, or —NO2;
- R7 and R8 combine to form a C3-C7 cycloalkyl, 5- to 8-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl;
- wherein each hydrogen atom in C3-C7 cycloalkyl, 5- to 8-membered heterocycloalkyl, C6-C10 aryl, or 5- to 7-membered heteroaryl is independently optionally substituted by deuterium, halogen, —ORe, —OC(O)Re, —OC(O)NReRf, —OC(═N)NReRf, —OS(O)Re, —OS(O)2Re, —OS(O)NReRf, —OS(O)2NReRf, —SRe, —S(O)Re, —S(O)2Re, —S(O)NReRf, —S(O)2NReRf, —NReRf, —NReC(O)Rf, —NReC(O)ORf, —NReC(O)NReRf, —NReS(O)Rf, —NReS(O)2Rf, —NReS(O)NReRf, —NReS(O)2NReRf, —C(O)Re, —C(O)ORe, —C(O)NReRf, —PReRf, —P(O)ReRf, —P(O)2ReRf, —P(O)NReRf, —P(O)2NReRf, —P(O)ORe, —P(O)2ORe, —CN, or —NO2;
- Y is O, S, NR9, or CR9R19;
- R9 and R19 are each independently H, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl, wherein each hydrogen atom in C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, or mono- or bicyclic heteroaryl is optionally substituted by a halogen, —ORe, —OC(O)Re, —OC(O)NReRf, —OC(═N)NReRf, —OS(O)Re, —OS(O)2Re, —OS(O)NReRf, —OS(O)2NReRf, —SRe, —S(O)Re, —S(O)2Re, —S(O)NReRf, —S(O)2NReRf, —NReRf, —NReC(O)Rf, —NReC(O)ORf, —NReC(O)NReRf, —NReS(O)Rf, —NReS(O)2Rf, —NReS(O)NReRf, —NReS(O)2NReRf, —C(O)Re, —C(O)ORe, —C(O)NReRf, —PReRf, —P(O)ReRf, —P(O)2ReRf, —P(O)NReRf, —P(O)2NReRf, —P(O)ORe, or —P(O)2ORe;
- each Ra, Rb, Rc, Rd, Re, and Rf is independently selected from the group consisting of H, deuterium, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, 3- to 7-membered heterocycloalkyl, C6-C10 aryl, 5- to 7-membered heteroaryl;
- each of Z′, Z2, Z3, Z4, Z5, and Z6 is independently N, NH, C or CH;
- p is 1, 2, 3, or 4;
- and
- t is 1, 2, 3, 4, or 5;
- or a pharmaceutically acceptable salt thereof.
16 more elements
-27. (canceled)
Dependencies are inferred from the claim text.